Search Results
Your search for this matches 25363 pages
Showing 11601 - 11650FDA Approves Rituximab Biosimilar
On July 24, the U.S. Food and Drug Administration (FDA) approved rituximab-pvvr -(Ruxience), a biosimilar to rituximab (Rituxan), for the treatment of adult patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and granulomatosis with polyangiitis and microscopic polyangi-itis....
Novel Therapeutics on the Horizon for Treating Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-induced peripheral neuropathy is a major clinical problem, and better therapies are needed for both its treatment and prevention. According to Charles Loprinzi, MD, a medical oncologist at the Mayo Clinic in Rochester, Minnesota, to devise better preventive and treatment approaches,...
Studies Find Trilaciclib May Improve Chemotherapy Experience for Patients With Small Cell Lung Cancer
In patients with extensive-stage small cell lung cancer (SCLC), adding trilaciclib to standard-of-care chemotherapy demonstrated meaningful delays in deterioration of myelosuppression-related symptoms, according to Jared Weiss, MD, of the UNC Lineberger Comprehensive Cancer Center, Chapel Hill,...
Notable Presentations at ASCO 2019 Included Studies in Sarcoma, Lymphoma, Myeloma, and Breast and Kidney Cancers
The 2019 ASCO Annual Meeting featured a wealth of presentations on important topics. In addition to our regular news coverage of the meeting, we present below some highlights of other studies that add to our knowledge base for treatment of various cancers. Olaratumab in Soft-Tissue Sarcoma...
What Causes Liver Injury During Treatment With Pembrolizumab?
Immunotherapy as a treatment for advanced solid cancers has rapidly evolved over the past decade—often yielding remarkable results. However, its use has also given way to new adverse effects, including drug-induced gastrointestinal and liver toxicities. “Checkpoint inhibitors are a...
Gender Equity
Diversity, inclusion, and gender equality were prevalent themes for 2019 that ran throughout the ASCO Annual Meeting. From the first year that featured free onsite child care for attendees, to a session on “Establishing a Mutually Respectful Environment in the Workplace,” as well as a Plenary...
How an Innovative AI-Based Smartphone Application Is Addressing Patients’ Palliative Care Needs
GUEST EDITOR Addressing the evolving needs of cancer survivors at various stages of their illness and care, Palliative Care in Oncology is guest edited by Jamie H. Von Roenn, MD, FASCO. Dr. Von Roenn is ASCO’s Vice President of Education, Science, and Professional Development. During the 2019...
BEACON CRC: Encorafenib/Binimetinib/Cetuximab Improves Survival in BRAF V600E–Mutated Metastatic Colorectal Cancer
The three-drug combination of encorafenib (a BRAF inhibitor), binimetinib (a MEK inhibitor), and cetuximab (an EGFR inhibitor) significantly improved overall survival in patients with BRAF-mutated metastatic colorectal cancer, according to the results of the phase III BEACON CRC clinical trial....
AI May Improve Efficiency and Accuracy of Digital Breast Tomosynthesis
Artificial intelligence (AI) may improve the efficiency and accuracy of an advanced imaging technology used to screen for breast cancer, according to a study published by Conant et al in Radiology: Artificial Intelligence. Digital breast tomosynthesis is an advanced method for cancer...
Cell-Free DNA Sequencing Highly Concordant With Tissue-Based Testing in the Detection of Microsatellite Instability Status
Microsatellite instability (MSI) is an important predictive biomarker of response to immune checkpoint blockade in solid cancers. However, despite recommendations by clinical practice guidelines, MSI is often not assessed, usually due to tissue insufficiency, unavailability, or infeasibility....
Can Lymph Node Response to Neoadjuvant Chemotherapy Predict Prognosis in Esophageal Cancer?
In a study published by Urakawa et al in Annals of Surgery, researchers found that the response of lymph nodes to neoadjuvant chemotherapy is more effective in predicting disease recurrence and patient survival in individuals with esophageal cancer than the response of primary tumors....
Prognostic Biomarker for Progression of Moderate Cervical Dysplasia
In a study published by Louvanto et al in Clinical Infectious Diseases, researchers investigated the ability of a DNA methylation panel to determine between disease progression and regression among women of childbearing age with untreated cervical intraepithelial dysplasia. In the majority of...
FDA Approves Pexidartinib for Tenosynovial Giant Cell Tumor
On August 2, the U.S. Food and Drug Administration (FDA) granted approval to pexidartinib (Turalio) capsules for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not responsive to improvement with...
What Causes Liver Injury During Treatment With Pembrolizumab?
Immunotherapy as a treatment for advanced solid cancers has rapidly evolved over the past decade—often yielding remarkable results. However, its use has also given way to new adverse effects, including drug-induced gastrointestinal and liver toxicities. “Checkpoint inhibitors are a game changer...
FDA Pipeline: Breakthrough Therapy for Melanoma, Investigational New Drug for Advanced Solid Tumors
This week, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to bempegaldesleukin in combination with nivolumab for advanced melanoma and cleared an investigational new drug application for a phase I trial of SB 11285 in advanced solid tumors. Breakthrough...
Can Treatment With Antibiotics Inhibit Malignant T Cells in Cutaneous T-Cell Lymphoma?
Many patients with cutaneous T-cell lymphoma contract Staphylococcus aureus infections in the skin. In a new study, researchers have shown that aggressive treatment with antibiotics for patients with these infections not only inhibits the staphylococcal bacteria—but also the cancer...
Psychological Stress and Cancer-Specific Mortality in Patients With Cervical Cancer
Results from a large cohort study showed that psychological stress is associated with increased cancer-specific mortality among women with cervical cancer, independent of tumor characteristics and treatment modality. The findings support the integration of psychological screening and intervention...
Post Hoc 5-Year Follow-up of Pembrolizumab vs Ipilimumab in Advanced Melanoma
In a post hoc 5-year follow-up of the KEYNOTE-006 trial reported in The Lancet Oncology, Robert et al found that pembrolizumab maintained overall and progression-free survival benefits over ipilimumab in patients with advanced melanoma. In the primary analysis from the trial, both pembrolizumab...
Overall Survival in MONALEESA-7
This week, we discuss an interim analysis of the MONALEESA-7 trial of the addition of ribociclib to endocrine therapy in pre- or perimenopausal women with advanced hormone receptor–positive, HER2-negative breast cancer. We also talk about a study that examined the relationship between the duration...
Adjuvant Radiotherapy After Radical Prostatectomy vs Radical Prostatectomy Alone in Patients With Positive Margins or Extracapsular Extension
In patients with prostate cancer with surgical positive margins or extracapsular extension of their disease, the risk of disease recurrence postprostatectomy is higher than in cases where the cancer cells are confined within the prostate. The Finnish FinnProstataX study investigated...
Global Burden of Pediatric and Adolescent Cancer in 2017
A recent analysis looked at the global burden of pediatric cancer through the lens of years of affected and lost life. This work shows a much greater burden of childhood cancer, placed largely in low- and middle-income countries, than previous estimates. The findings were published in The Lancet...
Survey Finds Majority of Americans Are Unfamiliar With Cutaneous Squamous Cell Carcinoma
Nearly-three quarters of Americans are not familiar with cutaneous squamous cell carcinoma, the second most common type of cancer in the United States, according to a new survey conducted by The Harris Poll on behalf of The Skin Cancer Foundation. Cutaneous squamous cell carcinoma is more common...
Pazopanib in Advanced Extraskeletal Myxoid Chondrosarcoma
Findings from a cohort of a phase II study reported by Stacchiotti et al in The Lancet Oncology indicated activity of the antiangiogenic agent pazopanib in advanced extraskeletal myxoid chondrosarcoma. As noted by the investigators, this rare sarcoma has low sensitivity to cytotoxic chemotherapy,...
Ten-Year Update on Standard Adjuvant Chemotherapy vs Capecitabine in Older Women With Early Breast Cancer
As reported in the Journal of Clinical Oncology by Muss et al, long-term findings from the phase III CALGB 49907 trial support the finding from the primary analysis—that standard adjuvant chemotherapy improved recurrence-free survival vs capecitabine in women aged 65 years or older with early ...
FDA Approves Pembrolizumab for Some Patients With PD-L1–Positive Esophageal Cancer
On July 30, the U.S. Food and Drug Administration (FDA) approved the programmed cell death protein 1 inhibitor pembrolizumab (Keytruda) as monotherapy for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express programmed ...
Overall Survival With the Addition of Ribociclib to Endocrine Therapy in Advanced HR-Positive, HER2-Negative Breast Cancer
As reported in The New England Journal of Medicine by Im et al, an interim analysis of the phase III MONALEESA-7 trial has shown an overall survival benefit with the addition of the cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor ribociclib to endocrine therapy in pre- or perimenopausal women...
WHO Releases Report on the Global Tobacco Epidemic
Many governments are making progress in the fight against tobacco, with 5 billion people today living in countries that have introduced smoking bans, warnings on packaging, and other effective tobacco control measures—four times more people than a decade ago. However, a new World Health...
Post Hoc Updated Survival Analysis of Adjuvant Chemoradiotherapy vs Radiotherapy in High-Risk Endometrial Cancer
As reported in The Lancet Oncology by de Boer et al, a post hoc updated survival analysis of the phase III PORTEC-3 trial has shown a significant overall survival benefit of adjuvant chemoradiotherapy vs radiotherapy alone in women with high-risk endometrial cancer. A benefit in failure-free...
Automated Breast Cancer Detection Assay Using Fine-Needle Aspiration May Aid Patients in Developing Countries
A new laboratory test developed to identify chemical changes to a group of cancer-related genes may be able to accurately detect which breast tumors are cancerous or benign. Such a test could result in a more timely diagnosis of breast cancer for women in developing countries with less access to...
Germline BRCA2 Mutations and Risk of Pediatric or Adolescent Lymphoma
A research letter published by Wang et al in JAMA Oncology has found that inherited mutations in the BRCA2 gene are linked to an increased risk for non-Hodgkin lymphoma in children and adolescents. “The BRCA family of genes are known to be linked to risk for breast and...
Use of BI-RADS Breast Density and BCSC Risk to Identify Women for Discussion of Supplemental Imaging
In a study reported in JAMA Internal Medicine, Kerlikowske et al found that the combined use of Breast Imaging Reporting and Data System (BI-RADS) breast density and Breast Cancer Surveillance Consortium (BCSC)-defined risk for breast cancer may be an effective way of identifying women with dense...
FDA Pipeline: Label Update for Durvalumab in NSCLC; Applications Accepted in Epithelioid Sarcoma, AML
Recently, the U.S. Food and Drug Administration (FDA) approved the inclusion of overall survival from the PACIFIC trial in the U.S. prescribing information for durvalumab and accepted applications for a new drug in the treatment of epithelioid sarcoma and two orphan drugs in the treatment of acute...
Conditional Reprogramming of Urine Cultures for Bladder Cancer
A research team led by investigators from Georgetown University Medical Center and Fudan University in China has devised a noninvasive and individualized technique for detecting and treating bladder cancer. Their findings were published by Jiang et al in Protein & Cell. The method uses a...
Deep Natural Language Processing of Oncology Radiology Reports
Scientists have demonstrated that an artificial intelligence (AI) tool can perform as well as human reviewers—and much more rapidly—in extracting clinical information regarding changes in tumors from unstructured radiology reports for patients with lung cancer. These findings were...
Pembrolizumab After Stereotactic Body Radiotherapy in Advanced NSCLC
In a Dutch phase II study reported in JAMA Oncology, Theelen et al found that although use of stereotactic body radiotherapy prior to pembrolizumab increased the objective response rate vs pembrolizumab alone in metastatic non–small cell lung cancer (NSCLC), the difference did not meet study...
Rates of Early-Onset Colorectal Cancer
This week, we discuss a study that found a disconnect between rates of colonoscopy and recent increases in colorectal cancer incidence in younger adults. In addition, Kimmie Ng, MD, MPH, of Dana-Farber Cancer Institute, offers her insights on the rising rates of colorectal cancer in young adults....
ASCO Now Accepting Research Project Applications for Research Survey Pool
ASCO’S CENTER FOR Research and Analytics (CENTRA) is now accepting research applications from ASCO members who wish to conduct surveys of the Society’s membership for research purposes. The Research Survey Pool (RSP) is a service made available to ASCO members who engage in survey research. It...
ASCO Answers Topic-Specific Booklet Bundle
FINDING TRUSTED resources to support some conversations with your patients can be challenging—ASCO is here to help. Use the ASCO Answers booklet bundle to guide discussions with patients and caregivers and provide them with the ideal take-home resource. This topic-specific booklet bundle includes...
Director of the FDA’s Oncology Center of Excellence Discusses Expanded Access, Accelerated Drug Approvals in Latest ASCO in Action Podcast
THE DIRECTOR OF the U.S. Food and Drug Administration’s (FDA) Oncology Center of Excellence (OCE), Richard Pazdur, MD, joins ASCO Chief Executive Officer Clifford A. Hudis, MD, FACP, FASCO, in the latest ASCO in Action Podcast to discuss the FDA’s new program to make it easier for physicians to...
ASCO, Conquer Cancer Congratulate 2019 Grant and Award Recipients
Conquer Cancer®, the ASCO Foundation, presented more than $7 million in grants and awards to exceptional oncology researchers at the 2019 ASCO Annual Meeting. ASCO and Conquer Cancer congratulate the recipients and offer their profound thanks to those who generously supported these awards. Visit...
CancerCare® Publishes Manifesto on the Importance of Patients’ Values in Treatment Decision-Making
CANCERCARE® has announced the publication of a patient manifesto that emphasizes the importance of including patients’ values and priorities in cancer treatment planning. This manifesto can be used to inform and advocate with policymakers, insurers, health-care administrators, electronic medical...
Parental Treatment Refusals: What Your Responsibilities Are When Mom and Dad Decline Cancer Treatment for a Child
In April 2019, a 3-year-old boy, Noah McAdams, missed the third round of chemotherapy for his acute lymphoblastic leukemia. His parents wanted instead to focus on alternative remedies of cannabidiol oil, alkaline water, mushroom tea, and herbal extracts. The sheriff was summoned; Noah’s parents...
Is It Time to Reevaluate the P Value in Biomedical Research?
Developed in 1925 by British statistician Sir Ronald Fisher, the P value is a measure that is ever-present in abstracts and studies, a small statistical tool that has enormous power to aid research being published in the literature or support drug approval. Over the past several years, however, a...
Expert Point of View: Sarina Anne Piha-Paul, MD, and Benjamin Besse, MD, PhD
THE INVITED discussants of the presentations on repotrectinib and AMG 510 were enthusiastic about these agents. Sarina Anne Piha-Paul, MD, of The University of Texas MD Anderson Cancer Center, discussed AMG 510, and Benjamin Besse, MD, PhD, Head of the Cancer Medicine Department at the Institut...
Brief Update on Clinical Trials of New Treatments in Gastrointestinal Cancers
The 2019 ASCO Annual Meeting provided attendees with an abundance of clinically relevant abstracts in gastrointestinal cancers. Briefly featured here are clinical trial updates on pembrolizumab in the second-line treatment of hepatocellular carcinoma (KEYNOTE-240 trial), laparoscopic vs open...
Friends of Cancer Research Launches Next Phase in Real-World Evidence Initiative
FRIENDS OF CANCER RESEARCH (Friends) is launching the next phase of its Real-World Evidence pilot project after a broad stakeholder meeting in February 2019. At the meeting, the U.S. Food and Drug Administration (FDA) and various data partners expressed interest in continuing to address several...
Two Investigational Agents Demonstrate Safety, Efficacy in Lung Cancer
A handful of investigational drugs in early-phase trials always create a buzz at ASCO Annual Meetings. Two that garnered attention this year, and could eventually change outcomes in the clinic, are the first-in-class KRAS inhibitor AMG 510 and the ROS1 inhibitor repotrectinib. Should late-phase...
Jason S. Lewis, PhD, Receives SNMMI Award for Outstanding Achievement in Basic Nuclear Medicine Science
Jason S. Lewis, PhD, has been named the 2019 recipient of the Paul C. Aebersold Award. Dr. Lewis is the Emily Tow Jackson Chair in Oncology and Vice Chair for Research and Chief Attending, Radiochemistry and Imaging Sciences Service, Department of Radiology at Memorial Sloan Kettering Cancer...
Update on Newer Treatments in Non-Hodgkin Lymphomas
As part of The ASCO Post’s coverage of the 2019 ASCO Annual Meeting, featured here are summaries of five abstracts of different clinical trials evaluating newer treatments for follicular and marginal zone lymphomas as well as diffuse large B-cell lymphoma. Follicular and Marginal Zone Lymphomas...
FDA Expands Indication for Pembrolizumab to Metastatic Small Cell Lung Cancer
ON JUNE 17, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the anti– programmed cell death protein 1 (PD-1) therapy pembrolizumab (Keytruda) as monotherapy for patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based...
